Author's response to reviews

Title: Approaches to discontinuing efalizumab: an open-label study of therapies for managing inflammatory recurrence

Authors:

   Kim A Papp (kapapp@probitymedical.com)
   Darryl Toth (dtoth@jet2.net)
   Les Rosoph (lesrosoph@hotmail.com)

Version: 2 Date: 15 August 2006

Author's response to reviews:

Each of the major and minor comments made by the reviewers were addressed including clarification of definitions of flare, rebound, inflammatory eruption, and PGA. Changes are tracked in the revised document.